CD274 and cancer: Currently, immune checkpoint (ICP) inhibitors, such as antibodies blocking PD-1/PD-L1 axis, have shown significant antitumor activity in many cancer types and have been approved by the FDA as a recommended therapy for cancer treatment [2].